6/26/2025

In the closing of the recent trading day, Moderna (MRNA) stood at $27.54, denoting a +2.53% move from the preceding trading day.

Source: Yahoo

6/26/2025

Moderna’s first quarter results were met with a negative market reaction, as revenue fell short of Wall Street expectations and declined sharply versus the prior year. Management attributed the performance primarily to the seasonal nature of respiratory vaccine sales and lower overall COVID vaccination rates, which have become more routine rather than urgent. CEO Stephane Bancel pointed to progress in cost reduction efforts, highlighting a 19% reduction in combined cost of sales, research and de

Source: Yahoo

6/25/2025

Chinese SinoVac Biotech Ltd. (Nasdaq: SVA) shares have been frozen since 2019 amid shareholder disputes when market cap was about $500 million SinoVac developed a wildly successful Covid vaccine and has over $10 billion in cash on balance sheet but investors have had no dividends or liquidity Current board is fending off a competing slate […] The post Seeking a Cure for Sickly Corporate Governance at SinoVac appeared first on CorpGov.

Source: Yahoo

6/25/2025

Moderna’s stock price has taken a beating over the past six months, shedding 33.6% of its value and falling to $26.85 per share. This was partly due to its softer quarterly results and may have investors wondering how to approach the situation.

Source: Yahoo

6/24/2025

We came across a bullish thesis on Moderna, Inc. (MRNA) on Natan’s Substack. In this article, we will summarize the bulls’ thesis on MRNA. Moderna, Inc. (MRNA)’s share was trading at $26.67 as of 13th June. MRNA’s trailing P/E was 7.06 according to Yahoo Finance. Moderna’s stock has fallen nearly 94% from its pandemic-era highs, reflecting deep […]

Source: Yahoo

6/24/2025

Moderna Inc. (NASDAQ:MRNA) is one of the best mid cap growth stocks to invest in now. On June 12, the US FDA expanded the approval for Moderna’s respiratory syncytial virus/RSV vaccine, mRESVIA (mRNA-1345). The vaccine is now approved for the prevention of lower respiratory tract disease/LRTD caused by RSV in individuals aged 18 to 59 […]

Source: Yahoo

6/23/2025

Investors are highly skeptical about the messenger RNA pioneer's ability to reinvent itself now that the COVID windfall has dried up.

Source: Finnhub

6/20/2025

In the most recent trading session, Moderna (MRNA) closed at $25.90, indicating a +1.97% shift from the previous trading day.

Source: Yahoo

6/20/2025

Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.

Source: Yahoo

6/18/2025

U.S. Senate Democratsdemanded on Wednesday Health Secretary Robert F. Kennedy Jr.make public the reviews on which his department said it basedits decision to cancel a contract for developing a bird...

Source: Finnhub

6/16/2025

Moderna, Inc. (NASDAQ:MRNA) Barclays Speaking the Science Call Series Call June 16, 2025 10:00 AM ETCompany ParticipantsLavina Talukdar - Senior VP &...

Source: SeekingAlpha

6/16/2025

The following slide deck was published by Moderna, Inc.

Source: SeekingAlpha

6/16/2025

Presenter SpeechHuidong Wang My name is Gena Wang. I'm SMID Cap biotech analyst at the Barclays. Thank you for joining our call today. We are very pleased to continue our -- annual speaking science...

Source: Finnhub

6/13/2025

Moderna (MRNA) closed the most recent trading day at $26.68, moving 2.45% from the previous trading session.

Source: Yahoo

6/13/2025

The major averages were mixed near noon with the Dow the laggard as a pullback in Boeing weighs on the Industrials index. U.S. initial jobless claims were unchanged at 248,000 in the week ended June 7, above expectations and holding at an eight-month high. Geopolitical concerns have also resurfaced; escalating tensions in the Middle East led to a sharp rise in oil prices and triggered safe-haven flows, which weighed on equities and the U.S. dollar. Meanwhile, U.S.-China trade progress continues

Source: Yahoo

6/13/2025

Health care stocks were leaning lower premarket Friday with the Health Care Select Sector SPDR Fund

Source: Yahoo

6/13/2025

The RSV shot, mRESVIA, secured U.S. approval on Thursday for use in at-risk adults aged 18 to 59 years, but needs the U.S. Centers for Disease Control and Prevention's recommendation before it is made available for the age group. Earlier this week, Health Secretary Robert F. Kennedy Jr. fired all 17 members of the panel, known as the Advisory Committee on Immunization Practices (ACIP) - a move health experts warn could undermine public confidence in available vaccines. The ACIP advises the CDC on who should get the shots after they are approved by the U.S. Food and Drug Administration.

Source: Yahoo

6/13/2025

The label expansion for Moderna’s jab arrives at a juncture in America’s changing vaccine regulatory landscape.

Source: Yahoo

6/13/2025

Moderna's shares fell 2.3%on Friday on concerns about whether a new CDC advisory panelwould back the use of the company's respiratory syncytial virusvaccine in a broader age group. ...

Source: Finnhub

6/13/2025

Moderna has announced that the FDA has approved 'mRESVIA' , its vaccine against respiratory syncytial virus , for the prevention of lower respiratory tract infections caused by RSV in adults aged 18...

Source: Finnhub